Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
RADIUM-223 CHLORIDE
BAYER (SOUTH EAST ASIA) PTE LTD
1000 kBq/ml
INJECTION, SOLUTION (RADIOPHARMACEUTICAL)
RADIUM-223 CHLORIDE 1100 kBq/ml
INTRAVENOUS
Prescription Only
Agilera Pharma AS
ACTIVE
2014-01-09
Xofigo_CCDSv2.1_15Jan2014 1. NAME OF THE MEDICINAL PRODUCT Xofigo solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 1000 kBq radium Ra 223 dichloride (radium-223 dichloride), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free ion. Each vial contains 6 ml of solution (6.0 MBq radium-223 dichloride at the reference date). Radium-223 is an alpha particle-emitter with a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq/ng. The six-stage-decay of radium-223 to lead-207 occurs via short-lived daughters, and is accompanied by a number of alpha, beta and gamma emissions with different energies and emission probabilities. The fraction of energy emitted from radium-223 and its daughters as alpha-particles is 95.3% (energy range of 5.0 -7.5 MeV). The fraction emitted as beta particles is 3.6% (average energies are 0.445 MeV and 0.492 MeV), and the fraction emitted as gamma-radiation is 1.1% (energy range of 0.01 - 1.27 MeV). 3. PHARMACEUTICAL FORM Solution for injection. 4. CLINICAL PARTICULARS 4.1 INDICATION(S) Xofigo is indicated for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. 4.2 DOSAGE AND METHOD OF ADMINISTRATION 4.2.1 METHOD OF ADMINISTRATION Xofigo is to be administered by slow intravenous injection (generally up to 1 minute). The intravenous access line or cannula must be flushed with isotonic saline before and after injection of Xofigo. For additional instructions on the use of the product see section ‘ Instructions for use/handling ’. 4.2.2 DOSAGE REGIMEN The dose regimen of Xofigo is 50 kBq per kg body weight, given at 4 week intervals for 6 Read the complete document
Xofigo_CCDSv6_ 1Nov2019 1. NAME OF THE MEDICINAL PRODUCT Xofigo solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 1100 kBq radium Ra 223 dichloride (radium-223 dichloride), corresponding to 0.58 ng radium-223, at the reference date. Radium is present in the solution as a free ion. Each vial contains 6 ml of solution (6.6 MBq radium-223 dichloride at the reference date). Radium-223 is an alpha particle-emitter with a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq/ng. The six-stage-decay of radium-223 to lead-207 occurs via short-lived daughters, and is accompanied by a number of alpha, beta and gamma emissions with different energies and emission probabilities. The fraction of energy emitted from radium-223 and its daughters as alpha-particles is 95.3% (energy range of 5.0 -7.5 MeV). The fraction emitted as beta particles is 3.6% (average energies are 0.445 MeV and 0.492 MeV), and the fraction emitted as gamma-radiation is 1.1% (energy range of 0.01 - 1.27 MeV). 3. PHARMACEUTICAL FORM Solution for injection. 4. CLINICAL PARTICULARS 4.1 INDICATION(S) Xofigo is indicated for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. 4.2 DOSAGE AND METHOD OF ADMINISTRATION 4.2.1 METHOD OF ADMINISTRATION Xofigo is to be administered by slow intravenous injection (generally up to 1 minute). The intravenous access line or cannula must be flushed with isotonic saline before and after injection of Xofigo. For additional instructions on the use of the product see section ‘Instructions for use/handling’. 4.2.2 DOSAGE REGIMEN The dose regimen of Xofigo is 55 kBq per kg body weight, given at 4 week intervals for 6 injections. Safety and efficacy beyond 6 injections with Xofigo have not been studied. For details on the calculation of the volume to be administered see section ‘Instructions for use/ handling’. _Elderly patients _ No overall differences in safety or efficacy Read the complete document